A single-center experience in use of tocilizumab in COVID-19 pneumonia in India

BACKGROUND: IL-6 receptor antagonist tocilizumab (TCZ) has been used in several reported studies in the treatment of COVID-19 pneumonia and pieces of evidence are still emerging. METHODS: All patients with COVID-19 pneumonia showing features of hyperinflammatory syndrome receiving TCZ at a tertiary...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Aditya, Kumar M, Krishna, Kumar, Abhishek, Nair, Ranjith K., Singh, Jasdeep, Chakrabarti, Ritwik, Kapoor, Rajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313049/
https://www.ncbi.nlm.nih.gov/pubmed/34334897
http://dx.doi.org/10.1016/j.mjafi.2021.05.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313049/
https://www.ncbi.nlm.nih.gov/pubmed/34334897
http://dx.doi.org/10.1016/j.mjafi.2021.05.022

Ejemplares similares